Invitation to Cosmo's Unaudited Full Year 2024 Financial Results Webcast on 6 March 2025
Cosmo Pharmaceuticals (SIX: COPN: C43) has announced it will release its unaudited Full-Year 2024 financial results on March 6, 2025, at 7:00 am CET. The company will host a live webcast presentation at 3:00 pm CET on the same day.
CEO Giovanni Di Napoli and CFO Svetlana Sigalova will present a detailed overview of the company's financial and operational performance, discuss strategic initiatives, growth opportunities, and future outlook. A Q&A session will follow the presentation.
The webcast will be accessible online with replay available for three months. The complete 2024 Annual Report will be published on March 20, 2025, at 7:00 am CET on the company's website.
Cosmo Pharmaceuticals (SIX: COPN: C43) ha annunciato che rilascerà i suoi risultati finanziari non verificati per l'anno 2024 il 6 marzo 2025 alle 7:00 CET. L'azienda ospiterà una presentazione in diretta tramite webcast alle 15:00 CET nello stesso giorno.
Il CEO Giovanni Di Napoli e il CFO Svetlana Sigalova presenteranno una panoramica dettagliata delle performance finanziarie e operative dell'azienda, discuteranno le iniziative strategiche, le opportunità di crescita e le prospettive future. Seguirà una sessione di domande e risposte dopo la presentazione.
Il webcast sarà accessibile online con replay disponibile per tre mesi. Il Rapporto Annuale 2024 completo sarà pubblicato il 20 marzo 2025 alle 7:00 CET sul sito web dell'azienda.
Cosmo Pharmaceuticals (SIX: COPN: C43) ha anunciado que publicará sus resultados financieros no auditados del año 2024 el 6 de marzo de 2025 a las 7:00 CET. La empresa llevará a cabo una presentación en vivo por webcast a las 15:00 CET el mismo día.
El CEO Giovanni Di Napoli y la CFO Svetlana Sigalova ofrecerán una visión detallada del rendimiento financiero y operativo de la empresa, discutirán iniciativas estratégicas, oportunidades de crecimiento y perspectivas futuras. A continuación, habrá una sesión de preguntas y respuestas.
El webcast será accesible en línea con repetición disponible durante tres meses. El Informe Anual 2024 completo será publicado el 20 de marzo de 2025 a las 7:00 CET en el sitio web de la compañía.
Cosmo Pharmaceuticals (SIX: COPN: C43)는 2024 회계연도 비감사 재무 결과를 2025년 3월 6일 오전 7시 CET에 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 3시에 라이브 웹캐스트 프레젠테이션을 진행할 예정입니다.
CEO 조반니 디 나폴리와 CFO 스베틀라나 시갈로바는 회사의 재무 및 운영 성과에 대한 상세한 개요를 제공하고, 전략적 이니셔티브, 성장 기회 및 미래 전망에 대해 논의할 것입니다. 프레젠테이션 후에는 질문 및 답변 세션이 이어질 것입니다.
웹캐스트는 온라인에서 접근할 수 있으며, 3개월 동안 재생 가능한 버전이 제공됩니다. 2024 연례 보고서는 2025년 3월 20일 오전 7시 CET에 회사 웹사이트에 게시될 예정입니다.
Cosmo Pharmaceuticals (SIX: COPN: C43) a annoncé qu'il publiera ses résultats financiers non audités pour l'année 2024 le 6 mars 2025 à 7h00 CET. L'entreprise organisera une présentation en direct par webcast le même jour à 15h00 CET.
Le PDG Giovanni Di Napoli et la CFO Svetlana Sigalova présenteront un aperçu détaillé des performances financières et opérationnelles de l'entreprise, discuteront des initiatives stratégiques, des opportunités de croissance et des perspectives futures. Une session de questions-réponses suivra la présentation.
Le webcast sera accessible en ligne avec une rediffusion disponible pendant trois mois. Le rapport annuel 2024 complet sera publié le 20 mars 2025 à 7h00 CET sur le site Web de l'entreprise.
Cosmo Pharmaceuticals (SIX: COPN: C43) hat bekanntgegeben, dass die uneingeschränkten Finanzzahlen für das Jahr 2024 am 6. März 2025 um 7:00 Uhr CET veröffentlicht werden. Das Unternehmen wird am selben Tag um 15:00 Uhr CET eine Live-Webcast-Präsentation veranstalten.
CEO Giovanni Di Napoli und CFO Svetlana Sigalova werden einen detaillierten Überblick über die finanziellen und operativen Leistungen des Unternehmens präsentieren sowie strategische Initiativen, Wachstumschancen und zukünftige Perspektiven diskutieren. Im Anschluss an die Präsentation wird es eine Frage- und Antwortsitzung geben.
Die Webcast-Präsentation wird online zugänglich sein, mit einer Wiederholung, die für drei Monate verfügbar ist. Der vollständige Jahresbericht 2024 wird am 20. März 2025 um 7:00 Uhr CET auf der Website des Unternehmens veröffentlicht.
- None.
- None.
Dublin, Ireland--(Newsfile Corp. - January 28, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN: C43) (“Cosmo”) announced today that it will publish its unaudited Full-Year 2024 results on Thursday, 6 March 2025 at 7:00 am CET.
Live conference call and video webcast presentation:
Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow on the same day at 3:00 pm CET.
Giovanni Di Napoli, Chief Executive Officer, and Svetlana Sigalova, Chief Financial Officer, will jointly present an in-depth overview of the Company’s latest financial and operational performance. They will also discuss strategic initiatives, growth opportunities, and outlook for the coming period. A Q&A session will follow, allowing stakeholders to engage directly with the leadership team.
Date: Thursday, 6 March 2025
Time: 3:00 pm CET
Participant Link: Live Webcast
Please note that there is a function to type in your questions via webcast.
Via phone:
Participants wishing to ask verbal questions via phone may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.
| Switzerland / Europe | +41 (0) 58 310 50 00 |
| United Kingdom | +44 (0) 207 107 06 13 |
| United States | +1 (1) 631 570 56 13 |
Replay:
The webcast, along with the presentation, will be available online shortly after the event and accessible for three months.
The 2024 Annual Report will be available for download on Thursday, 20 March 2025, as of 7:00 am CET at www.cosmopharma.com.
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Upcoming Events
2024 Full-Year Results (unaudited) March 6, 2025
J.P. Morgan European Opportunities Forum, London March 12, 2025
2024 Annual Report Publication March 20, 2025
26th Kepler Cheuvreux Swiss Seminar, Zurich March 20, 2025
For further information, please contact
Hazel Winchester, Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com
Attachments
250128_Cosmo_Invite_Unaudited FY2024_6Mar2025_Final
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238676
FAQ
When will Cosmo Pharmaceuticals release its Full-Year 2024 financial results?
When is Cosmo's 2024 financial results webcast presentation?
Who will present at Cosmo's 2024 financial results webcast?
When will Cosmo's 2024 Annual Report be available?
